Plasmodium falciparum: The effects of atovaquone resistance on respiration

Experimental Parasitology

Volumn 98, Issue 4, 2001, Pages 180-187

  Suswam, Esther ^a   Kyle, Dennis ^b   Lang Unnasch, Naomi ^a  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ATOVAQUONE; CYTOCHROME B; FLOXACRINE; MEPACRINE; OXYGEN; SALICYLHYDROXAMIC ACID; UNCLASSIFIED DRUG; WR 243251;

ARTICLE; BREATHING; CROSS RESISTANCE; DRUG POTENTIATION; ENZYME INHIBITION; NONHUMAN; OXYGEN CONSUMPTION; PARASITE SURVIVAL; PARASITOSIS; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; RESPIRATORY SYSTEM;

PLASMODIUM FALCIPARUM;

EID: 0034805433     PISSN: 00144894     EISSN: None     Source Type: Journal    
DOI: 10.1006/expr.2001.4639     Document Type: Article

References (15)

1. Antimalarial activity of WR 243251, a dihydroacridinedione
2. Interactions of atovaquone with other antimalarial drugs against Plasmodium falciparum in vitro
3. Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique
4. Mitochondria of mammalian Plasmodium spp
5. Site of action of the antimalarial hydroxynapthoquinone, 2-[trans-4-(4′-chlorphenyl) cyclohexyl]-3-hydroxy-1,4-napthoquinone (566C80)
6. Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for the treatment of acute uncomplicated malaria in Thailand
7. Molecular biology of the alternative oxidase
8. Plasmodium falciparum: Cyanide-resistant oxygen consumption
9. Alternative oxidase inhibitors potentiate the activity of atovaquone on Plasmodium falciparum
10. Mutants of Toxoplasma gondii resistant to atovaquone (566C80) or decoquinate
11. Therapy with atovaquone for Cryptosporidium parvum infection in neonatal severe combined immunodeficiency mice
12. Atovaquone, a broad spectum antiparasitic drug, collapses mitochondrial membrane potential in a malaria parasite
13. Mitochondrial physiology as a target for atovaquone and other antimalarials